Historically, the prognosis for individuals diagnosed with lung cancer has been bleak.
However, the past 10 years have seen important advances in treatment and diagnosis which …

This guideline is based on a comprehensive review of the literature on pulmonary nodules
and expert opinion. Although the management pathway for the majority of nodules detected …

Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC)
is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative …

Purpose To evaluate, in Japan Clinical Oncology Group study 0403, the safety and efficacy
of stereotactic body radiation therapy (SBRT) in patients with T1N0M0 non-small cell lung …

To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …

Non–small cell lung cancer (NSCLC) is the leading cause of cancer‐related death in the
United States. With the implementation of lung cancer screening, the number and proportion …

Lung cancer is the leading cause of cancer mortality, and radiotherapy plays a key role in
both curative and palliative treatments for this disease. Recent advances include stereotactic …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Non-Small Cell Lung Cancer (NSCLC) focuses on the principles of radiation therapy …

BACKGROUND The authors evaluated the efficacy, patterns of failure, and toxicity of
stereotactic ablative radiotherapy (SABR) for patients with medically inoperable, clinical …

Image-guided stereotactic ablative radiotherapy (SABR; also called stereotactic body
radiotherapy or radiosurgery) has become a standard treatment for medically inoperable …